Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Evusheld

AstraZeneca AZ

AZ’s Brilinta disappoints in stroke trial

Antiplatelet drug fails to demonstrate significant benefit in ischaemic stroke

Novartis building

NICE backs Novartis’ Entresto for heart failure

But approves narrower indication than has been authorised by Scotland's SMC

Celgene building

Wales backs NHS use of Abraxane despite NICE rejection

Overrules UK decision and will maintain access to Celgene’s pancreatic cancer drug

- PMLiVE

NICE promises UK to lead Europe for cancer drug approvals

But industry says running the new CDF will present NICE with a ‘hugely challenging’ task

AZ and Roche fund PatientsLikeMe cancer patient outcomes study

The online patient network's cancer experience research will also involve M2Gen

AstraZeneca AZ global R&D corporate HQ

AZ’s influenza drug fast tracked in US

FDA expedites MEDI8852 to help meet an acute need for new flu treatments

National Institute for Health and Care Excellence NICE logo

NICE’s rejection of Imbruvica ‘reveals appraisal process flaws’

Leukaemia charity says the cost-effectiveness body can't cope with uncertainty

AstraZeneca AZ global R&D corporate HQ

AZ offloads more products in slimming drive

Will invest Moventig, Plendil and Imdur proceeds in its R&D pipeline

AstraZeneca AZ global R&D corporate HQ

AZ’s tremelimumab fails mesothelioma trial

FDA-designated breakthrough therapy did not demonstrate increase in overall survival

- PMLiVE

New UK Cancer Drugs Fund takes shape

NICE to manage access to cancer treatments from 1 July

- PMLiVE

Pharma forms Parkinson’s disease trials consortium

Hopes to make clinical trials “smarter” through sharing of past PD trial data

- PMLiVE

AstraZeneca wins EU approvals for Zurampic and Brilique

Its gout drug receives a licence and antiplatelet therapy gains a new indication

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links